Přehled o publikaci
2025
Changes in metabolite profiles in the cerebrospinal fluid and in human neuronal cells upon tick-borne encephalitis virus infection
SUYAMA, Satoshi; Sally BOXALL; Benjamin GRACE; Andrea FOŘTOVÁ; Martina PÝCHOVÁ et. al.Základní údaje
Originální název
Changes in metabolite profiles in the cerebrospinal fluid and in human neuronal cells upon tick-borne encephalitis virus infection
Autoři
SUYAMA, Satoshi; Sally BOXALL; Benjamin GRACE; Andrea FOŘTOVÁ; Martina PÝCHOVÁ; Lenka KRBKOVÁ; Rupasri MANDAL; David WISHART; Diane E GRIFFIN; Daniel RŮŽEK a Niluka GOONAWARDANE
Vydání
Journal of neuroinflammation, London, BioMed Central Ltd, 2025, 1742-2094
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Organizace
Lékařská fakulta – Masarykova univerzita – Repozitář
UT WoS
001508094700001
EID Scopus
2-s2.0-105007994515
Klíčová slova anglicky
Tick-borne encephalitis virus; Cerebrospinal fluid; Human motor neurons; Metabolomics; Pro-inflammatory cytokines; Chemokines; Neuroinflammation
Návaznosti
LX22NPO5103, projekt VaV. NU22-05-00659, projekt VaV.
Změněno: 24. 6. 2025 00:50, RNDr. Daniel Jakubík
Anotace
V originále
gt;= 3.2) higher in encephalitis patients compared to the meningitis group. CSF urocanic acid levels were significantly lower in patients with encephalitis compared to those with meningitis (p = 0.012209). Follow-up analyses showed fluctuations in the levels of O-phosphoethanolamine, succinic acid, and L-proline in the encephalitis group, and pyruvic acid in the meningitis group. TBEV-infection of hMNs increased the production of SAM, FBP1 and PEP in a time-dependent manner. Depletion of the metabolites with characterised pharmacological inhibitors led to a concentration-dependent attenuation of virus growth, validating the identified changes as key mediators of TBEV infection.ConclusionsOur findings reveal that the neurological disease outcome of TBEV infection is associated with specific and dynamic metabolic signatures in the cerebrospinal fluid. We describe a new in vitro model for in-depth studies of TBEV-induced neuropathogenesis, in which the depletion of identified metabolites limits virus infection. Collectively, this reveals new biomarkers that can differentiate and predict TBEV-associated neurological disease. Additionally, we have identified novel therapeutic targets with the potential to significantly improve patient outcomes and deepen our understanding of TBEV pathogenesis.